Not sure about the first 2 partnership options. It is selling away our competitive advantage. If we do that we might as well not proceed with developing our own product.
Faast tracked FDA would be great - wonder when we can expect an update on that. Would significantly increase the value of a partnership.
Good to hear they dont think we will run out of money soon. Looking forward to seeing the black and white in the quarterly.
My thoughts on the AHZ AGM presentation, page-6
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$10.00 |
Change
-0.150(1.48%) |
Mkt cap ! $211.3M | |||
| Open | High | Low | Value | Volume |
| $10.26 | $10.35 | $9.80 | $295.8K | 29.56K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 22 | $9.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.00 | 2758 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |